Biomimetic, synthetic HDL nanostructures for lymphoma

Shuo Yang, Marina G. Damiano, Heng Zhang, Sushant Tripathy, Andrea J. Luthi, Jonathan S. Rink, Andrey V. Ugolkov, Amareshwar T K Singh, Sandeep S. Dave, Leo I. Gordon*, C. Shad Thaxton

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

92 Scopus citations


New therapies that challenge existing paradigms are needed for the treatment of cancer. We report a nanoparticle-enabled therapeutic approach to B-cell lymphoma using synthetic high density lipoprotein nanoparticles (HDL-NPs). HDL-NPs are synthesized using a gold nanoparticle template to control conjugate size and ensure a spherical shape. Like natural HDLs, biomimetic HDL-NPs target scavenger receptor type B-1, a high-affinity HDL receptor expressed by lymphoma cells. Functionally, compared with natural HDL, the gold NP template enables differential manipulation of cellular cholesterol flux in lymphoma cells, promoting cellular cholesterol efflux and limiting cholesterol delivery. This combination of scavenger receptor type B-1 binding and relative cholesterol starvation selectively induces apoptosis. HDL-NP treatment of mice bearing B-cell lymphoma xenografts selectively inhibits B-cell lymphoma growth. As such, HDL-NPs are biofunctional therapeutic agents, whose mechanism of action is enabled by the presence of a synthetic nanotemplate. HDL-NPs are active in B-cell lymphomas and potentially, other malignancies or diseases of pathologic cholesterol accumulation.

Original languageEnglish (US)
Pages (from-to)2511-2516
Number of pages6
JournalProceedings of the National Academy of Sciences of the United States of America
Issue number7
StatePublished - Feb 12 2013


  • Biologic
  • Nanotechnology
  • Therapy

ASJC Scopus subject areas

  • General

Fingerprint Dive into the research topics of 'Biomimetic, synthetic HDL nanostructures for lymphoma'. Together they form a unique fingerprint.

Cite this